Form 4: Lexaria Bioscience Corp. Director Acquires 5,000 Stock Options

Sentiment:

SEC Form 4 Filing


Catherine C. Turkel, a director of Lexaria Bioscience Corp., acquired 5,000 stock options on April 26, 2024.

Summary

  • On April 26, 2024, Catherine C. Turkel, a director of Lexaria Bioscience Corp., acquired 5,000 stock options with an exercise price of $2.36.
  • These options are exercisable from April 26, 2024, and expire on April 26, 2029.
  • Following this transaction, Ms. Turkel directly owns 15,000 stock options.
  • Ms. Turkel also disposed of 1,500 common shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider transaction, which is neutral in sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company directors.

Stakeholder Impact

  • The acquisition of stock options by a director could be viewed positively by shareholders, as it aligns the director's interests with the company's long-term success.

Key Dates

DateDescription
09/02/2022Date exercisable for stock options with an exercise price of $3.04, expiring on 09/02/2027
10/12/2022Date exercisable for stock options with an exercise price of $1.96, expiring on 10/12/2027
07/25/2023Date exercisable for stock options with an exercise price of $0.87, expiring on 07/25/2028
04/26/2024Date of transaction and date exercisable for stock options with an exercise price of $2.36, expiring on 04/26/2029
04/26/2029Expiration date for stock options with an exercise price of $2.36

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.